Meeting
2023 ASCO Gastrointestinal Cancers Symposium
Severe enterocolitis with capecitabine (CAPE) is not a predictor of gastrointestinal (GI) toxicity with infusional 5-fluorouracil (5-FU)–based regimens: An institutional analysis.
Authors
Marie Parish
Mayo Clinic, Rochester, MN;
Marie Parish , Ronald Cox , Aditya V. Shreenivas , Amit Mahipal , Sakti Chakrabarti
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Cancers of the Colon, Rectum, and Anus
Track
Colorectal Cancer,Anal Cancer
Sub Track
Symptoms, Toxicities, and Whole-Person Care
Citation
J Clin Oncol 41, 2023 (suppl 4; abstr 89)
DOI
10.1200/JCO.2023.41.4_suppl.89
Abstract #
89
Poster Bd #
E6
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
A novel genetic marker of fluoropyrimidine-induced cardiovascular toxicity.
First Author: Claire Palles
Poster
2021 Gastrointestinal Cancers Symposium
Durvalumab (D) and PET-directed chemoradiation (CRT) after induction FOLFOX for esophageal adenocarcinoma.
First Author: Geoffrey Yuyat Ku
Poster
2020 Gastrointestinal Cancers Symposium
Durvalumab (D) and PET-directed chemoradiation (CRT) after induction FOLFOX for esophageal adenocarcinoma.
First Author: Michele Ly
Poster
2014 Gastrointestinal Cancers Symposium
The safety of chemotherapy for colorectal cancer patients with hepatitis C virus infection.
First Author: Kenji Tomizawa